Careteq Retains ASX Listing After Divesting Embedded Health Solutions, Focuses on Expanding HMR Referrals Marketplace

ASX Affirms Continued Quotation After Strategic Divestment

Careteq Limited received formal assurance from the Australian Securities Exchange that its securities will continue to be listed after divesting its Embedded Health Solutions subsidiary. This milestone resolves prior regulatory uncertainties related to the divestment. Following discussions about Careteq’s operational plans, strategic goals, and intended use of proceeds from the disposal, the ASX confirmed the company maintains sufficient operations and financial stability to justify ongoing quotation.

This approval removes a significant regulatory obstacle, allowing Careteq to confidently execute its renewed business strategy. The ASX’s endorsement indicates satisfaction with Careteq’s strategic direction and the viability of the HMR Referrals platform as a standalone business capable of meeting listing requirements.

HMR Referrals Marketplace Becomes Core Business Post-Divestment

Post-divestment, HMR Referrals stands as Careteq’s sole operating business. This SaaS two-sided marketplace connects general practitioners with credentialed pharmacists to facilitate Home Medicines Reviews, a government-subsidised service reimbursed under Medicare Benefits Schedule Item 900. This specialization places Careteq within a defined regulatory and reimbursement framework, providing revenue stability linked to government health policies.

The platform’s network boasts over 500 accredited pharmacists, roughly 80 GP clinics, and 400 GPs nationwide, establishing a substantial competitive moat. The scale of this two-sided marketplace enhances value for participants on both sides, reflecting significant adoption and presence in key regions.

March Quarter Results: Positive Cash Flow and Revenue Growth

During the March quarter, Careteq reported customer receipts totaling $2.192 million, up from $2.098 million in the December quarter. This growth occurred amid operational transitions including the EHS divestment and a capital raise, indicating sustained demand for HMR Referrals services.

The company achieved positive net operating cash flow of $14,000 in the March quarter, reversing a $95,000 operating cash outflow from the prior quarter. This improvement signals progress toward balancing revenue and operating expenses. Careteq plans to release further updates on June quarter performance with its Q4-FY26 Activities Report and Appendix 4C cash flow statement later this month.

Strategic Priorities for the Next 12 Months: Network Expansion and Clinic Activation

Careteq’s three main strategic priorities include deepening engagement within its accredited pharmacist and GP clinic networks, particularly in targeted geographic areas. The company also aims to integrate its platform with leading practice management systems to streamline provider adoption and increase user retention.

Additionally, Careteq intends to implement a standardized clinic activation program to convert under-utilized Home Medicines Review capacity into increased referral volumes, addressing latent demand without necessarily expanding the clinic network. The third priority involves exploring adjacent healthcare programs, potentially extending the HMR Referrals marketplace into community pharmacy initiatives leveraging existing infrastructure.

Advancing Artificial Intelligence Strategy and Strategic Opportunity Assessment

Careteq has indicated plans to develop an artificial intelligence strategy as part of its long-term growth. While specifics and timelines remain undisclosed, the company is monitoring healthcare technology trends and considering capability partnerships, technology collaborations, and strategic acquisitions to support growth and AI integration.

The Board emphasizes a disciplined approach to evaluating complementary opportunities, focusing on long-term shareholder value creation. This suggests selective engagement in acquisitions or partnerships aligned with the company’s strategic objectives, aiming to enhance the HMR Referrals marketplace’s value proposition through AI capabilities.

Capital Raising Completion and Fund Allocation

During the March quarter, Careteq completed a two-tranche capital raise. Combined with proceeds from the EHS divestment, these funds support operational activities aligned with the company’s strategic priorities. While specific fund allocations were referenced in the announcement, they were not detailed in the provided text. Investments will be phased across clinic activation, pharmacist recruitment, and sector engagement to allow management to monitor returns and adjust resource deployment accordingly.

The Board considers the current funding sufficient for planned activities over the next 12 months, expecting operational cash generation to complement capital deployment. Careteq commits to transparent reporting on capital use in quarterly activity reports, enhancing investor oversight of progress against strategic goals.

Operating Within Medicare Benefits Schedule Framework and Home Medicines Review Market

Careteq operates within Australia’s government-subsidised healthcare market, specifically under Medicare Benefits Schedule Item 900, which governs Home Medicines Review reimbursements. This framework offers revenue predictability but ties the company’s financial performance to government funding decisions and policy continuity.

The company’s focus on converting under-utilized HMR capacity highlights potential to increase referral volumes within existing reimbursement structures without requiring policy changes. This positions Careteq apart from consumer-facing telehealth markets by relying on stable government funding rather than consumer out-of-pocket payments.

Exploration of adjacent community pharmacy programs suggests potential to broaden the marketplace’s scope using existing networks, potentially expanding addressable markets without extensive new provider recruitment.

Competitive Advantage Through Network Scale and Integration

The HMR Referrals platform benefits from network effects, with over 500 accredited pharmacists and 400 GPs across about 80 clinics nationally. This scale creates switching costs and a competitive moat by enhancing platform utility for both pharmacists and GPs, fostering mutual dependencies that deter displacement by competitors.

Careteq’s strategy to deepen network engagement in targeted regions, alongside integration with leading practice management systems, aims to embed the platform more deeply within healthcare workflows, strengthening competitive positioning through both network density and technological integration.

Financial Sustainability and Path Toward Profitability

The shift to positive operating cash flow in the March quarter marks a key operational milestone, indicating progress toward self-sustaining business operations. Generating $14,000 in net operating cash flow on $2.192 million in receipts amid significant corporate restructuring underscores improving unit economics and operational efficiency.

The Board’s confidence in funding sufficiency depends on maintaining revenue growth and managing expenses. Successful execution of growth initiatives could accelerate the path to profitability, while challenges in clinic activation or pharmacist recruitment could extend capital needs beyond the 12-month horizon. The phased capital deployment approach provides flexibility to adjust spending based on results.

Risks and Execution Challenges

Careteq’s success hinges on effective execution of network expansion, clinic activation, and evaluation of complementary opportunities. Execution risks include potential underperformance in referral volume growth or higher-than-expected recruitment costs, which could delay profitability and increase capital requirements.

The company’s interest in acquisitions and partnerships introduces integration risks, especially given modest positive cash flow and limited capital. Additionally, reliance on government reimbursement for HMR services exposes Careteq to regulatory risks beyond its control, including potential changes in health policy or funding that could impact revenue. The announcement does not disclose the proportion of customer receipts derived specifically from MBS-funded HMR services versus other revenue streams.